<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39311203</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2036-7430</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Infectious disease reports</Title><ISOAbbreviation>Infect Dis Rep</ISOAbbreviation></Journal><ArticleTitle>Lipid Metabolism Disorders as Diagnostic Biosignatures in Sepsis.</ArticleTitle><Pagination><StartPage>806</StartPage><EndPage>819</EndPage><MedlinePgn>806-819</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/idr16050062</ELocationID><Abstract><AbstractText>Critical illness causes disturbances in lipid metabolism. Here, we investigated the levels of apolipoprotein A-IV (apoA-IV), a regulator of triglyceride and cholesterol metabolism, in human sepsis. ApoA-IV (analyzed in 156 patients with systemic inflammatory response syndrome (SIRS)/sepsis) and cholesteryl ester (CE) (analyzed in 121 of these patients) were lower in patients compared to 43 healthy controls. In contrast, triglyceride (TG) levels were elevated in patients. ApoA-IV levels in plasma of the patients did not correlate with these lipids. Patients with SIRS, sepsis or septic shock had comparable apoA-IV, TG, CE and free cholesterol (FC) levels. Patients on dialysis had significantly lower CE levels, whereas apoA-IV levels did not change much. CE levels were elevated in patients with viral sepsis due to SARS-CoV-2 infection in comparison to SIRS/sepsis patients not infected by this virus. CE levels correlated negatively with procalcitonin, interleukin-6 and bilirubin, while TGs were positively associated with bilirubin and C-reactive protein. ApoA-IV, TG, CE and FC levels were not associated with bacterial infection or survival. In conclusion, this analysis suggests that CE levels decline in sepsis-related renal failure and also shows that plasma apoA-IV and CE levels are early biomarkers of sepsis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Birner</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mester</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebisch</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4886-0811</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Höring</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3651-392X</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2222-2926</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavel</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9473-3509</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buechler</LastName><ForeName>Christa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5635-3994</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Infect Dis Rep</MedlineTA><NlmUniqueID>101537203</NlmUniqueID><ISSNLinking>2036-7430</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">apolipoprotein</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">septic shock</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">triglyceride</Keyword></KeywordList><CoiStatement>Martina Müller (travel grants and scientific presentations): United European Gastroenterology, Abbvie Germany, Falk Foundation, Germany.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39311203</ArticleId><ArticleId IdType="pmc">PMC11417812</ArticleId><ArticleId IdType="doi">10.3390/idr16050062</ArticleId><ArticleId IdType="pii">idr16050062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: Biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag. 2007;3:491–502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291326</ArticleId><ArticleId IdType="pubmed">17969379</ArticleId></ArticleIdList></Reference><Reference><Citation>Florea G., Tudorache I.F., Fuior E.V., Ionita R., Dumitrescu M., Fenyo I.M., Bivol V.G., Gafencu A.V. Apolipoprotein A-II, a Player in Multiple Processes and Diseases. Biomedicines. 2022;10:1578. doi: 10.3390/biomedicines10071578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10071578</ArticleId><ArticleId IdType="pmc">PMC9313276</ArticleId><ArticleId IdType="pubmed">35884883</ArticleId></ArticleIdList></Reference><Reference><Citation>Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J. Lipid Res. 2004;45:1169–1196. doi: 10.1194/jlr.R300019-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R300019-JLR200</ArticleId><ArticleId IdType="pubmed">15102878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalska K., Sabatowska Z., Forycka J., Mlynarska E., Franczyk B., Rysz J. The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management. Biomedicines. 2022;10:2320. doi: 10.3390/biomedicines10092320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092320</ArticleId><ArticleId IdType="pmc">PMC9496398</ArticleId><ArticleId IdType="pubmed">36140421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Luo Z., He H., Shen B., Liang J., Zhang J., Ye J., Xu Y., Wang Z., Ye D., et al. Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. Front. Med. 2021;8:585851. doi: 10.3389/fmed.2021.585851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.585851</ArticleId><ArticleId IdType="pmc">PMC8187559</ArticleId><ArticleId IdType="pubmed">34124081</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlage S., Gnewuch C., Liebisch G., Wolf Z., Audebert F.X., Gluck T., Frohlich D., Kramer B.K., Rothe G., Schmitz G. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35:1877–1885. doi: 10.1007/s00134-009-1609-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-009-1609-y</ArticleId><ArticleId IdType="pubmed">19669126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmaenner D.A., Kleyman A., Press A., Bauer M., Singer M. The Many Roles of Cholesterol in Sepsis: A Review. Am. J. Respir. Crit. Care Med. 2022;205:388–396. doi: 10.1164/rccm.202105-1197TR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202105-1197TR</ArticleId><ArticleId IdType="pmc">PMC8886946</ArticleId><ArticleId IdType="pubmed">34715007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N.K., Ferreira B.L., Tashima A.K., Brunialti M.K.C., Torquato R.J.S., Bafi A., Assuncao M., Azevedo L.C.P., Salomao R. Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis. Clin. Proteomics. 2019;16:29. doi: 10.1186/s12014-019-9252-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-019-9252-2</ArticleId><ArticleId IdType="pmc">PMC6631513</ArticleId><ArticleId IdType="pubmed">31341447</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker G., Leeuwenburgh C., Brusko T., Moldawer L., Reddy S.T., Guirgis F.W. Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness. J. Clin. Med. 2021;10:1693. doi: 10.3390/jcm10081693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081693</ArticleId><ArticleId IdType="pmc">PMC8071007</ArticleId><ArticleId IdType="pubmed">33920038</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakike E., Giamarellos-Bourboulis E.J., Kyprianou M., Fleischmann-Struzek C., Pletz M.W., Netea M.G., Reinhart K., Kyriazopoulou E. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. Crit. Care Med. 2021;49:2042–2057. doi: 10.1097/CCM.0000000000005195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005195</ArticleId><ArticleId IdType="pmc">PMC8594513</ArticleId><ArticleId IdType="pubmed">34259663</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques M.O., Abdo A., Silva P.B., Silva Junior A., Alves L.B.O., Costa J.V.G., Martin J., Bachour P., Baiocchi O.C.G. Soluble CD137 as a potential biomarker for severe COVID-19. Immunol. Lett. 2022;248:119–122. doi: 10.1016/j.imlet.2022.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2022.07.003</ArticleId><ArticleId IdType="pmc">PMC9262646</ArticleId><ArticleId IdType="pubmed">35810991</ArticleId></ArticleIdList></Reference><Reference><Citation>Begue F., Chemello K., Veeren B., Lortat-Jacob B., Tran-Dinh A., Zappella N., Snauwaert A., Robert T., Rondeau P., Lagrange-Xelot M., et al. Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study. Int. J. Mol. Sci. 2023;24:4605. doi: 10.3390/ijms24054605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054605</ArticleId><ArticleId IdType="pmc">PMC10003429</ArticleId><ArticleId IdType="pubmed">36902035</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold K.R. The bidirectional interaction of COVID-19 infections and lipoproteins. Best Pract. Res. Clin. Endocrinol. Metab. 2023;37:101751. doi: 10.1016/j.beem.2023.101751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101751</ArticleId><ArticleId IdType="pmc">PMC9951034</ArticleId><ArticleId IdType="pubmed">36894344</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J., Ko C.W., Tso P., Bhargava A. Apolipoprotein A-IV: A Multifunctional Protein Involved in Protection against Atherosclerosis and Diabetes. Cells. 2019;8:319. doi: 10.3390/cells8040319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8040319</ArticleId><ArticleId IdType="pmc">PMC6523623</ArticleId><ArticleId IdType="pubmed">30959835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohan A.B., Wang F., Lo C.M., Liu M., Tso P. ApoA-IV: Current and emerging roles in intestinal lipid metabolism, glucose homeostasis, and satiety. Am. J. Physiol. Gastrointest. Liver Physiol. 2015;308:G472–G481. doi: 10.1152/ajpgi.00098.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00098.2014</ArticleId><ArticleId IdType="pmc">PMC4360046</ArticleId><ArticleId IdType="pubmed">25591862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallongeville J., Lebel P., Parra H.J., Luc G., Fruchart J.C. Postprandial lipaemia is associated with increased levels of apolipoprotein A-IV in the triacylglycerol-rich fraction and decreased levels in the denser plasma fractions. Br. J. Nutr. 1997;77:213–223. doi: 10.1079/BJN19970025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/BJN19970025</ArticleId><ArticleId IdType="pubmed">9135368</ArticleId></ArticleIdList></Reference><Reference><Citation>Seishima M., Noma A., Torizawa H., Muto Y. Changes of serum apolipoprotein levels after oral administration of fat in human subjects. Atherosclerosis. 1988;73:39–43. doi: 10.1016/0021-9150(88)90161-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(88)90161-X</ArticleId><ArticleId IdType="pubmed">3178930</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde D., Ostos M.A., Badell E., Garcia-Otin A.L., Pidoux J., Castro G., Zakin M.M., Scott-Algara D. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 2004;24:756–761. doi: 10.1161/01.ATV.0000119353.03690.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000119353.03690.22</ArticleId><ArticleId IdType="pubmed">14751811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vowinkel T., Mori M., Krieglstein C.F., Russell J., Saijo F., Bharwani S., Turnage R.H., Davidson W.S., Tso P., Granger D.N., et al. Apolipoprotein A-IV inhibits experimental colitis. J. Clin. Investig. 2004;114:260–269. doi: 10.1172/JCI200421233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200421233</ArticleId><ArticleId IdType="pmc">PMC450164</ArticleId><ArticleId IdType="pubmed">15254593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearston K., Tan J.T.M., Cochran B.J., Rye K.A. Inhibition of Vascular Inflammation by Apolipoprotein A-IV. Front. Cardiovasc. Med. 2022;9:901408. doi: 10.3389/fcvm.2022.901408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.901408</ArticleId><ArticleId IdType="pmc">PMC9279673</ArticleId><ArticleId IdType="pubmed">35845068</ArticleId></ArticleIdList></Reference><Reference><Citation>Roula D., Theiler A., Luschnig P., Sturm G.J., Tomazic P.V., Marsche G., Heinemann A., Sturm E.M. Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and is reduced in treatment-naive allergic patients and allergen-challenged mice. Allergy. 2020;75:392–402. doi: 10.1111/all.14022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14022</ArticleId><ArticleId IdType="pmc">PMC7065107</ArticleId><ArticleId IdType="pubmed">31408538</ArticleId></ArticleIdList></Reference><Reference><Citation>Khovidhunkit W., Duchateau P.N., Medzihradszky K.F., Moser A.H., Naya-Vigne J., Shigenaga J.K., Kane J.P., Grunfeld C., Feingold K.R. Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis. 2004;176:37–44. doi: 10.1016/j.atherosclerosis.2004.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2004.04.018</ArticleId><ArticleId IdType="pubmed">15306172</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T., Bai J., Yang D., Huang L., Fan H.F., Zhang D.W., Liu T., Lu G. Identification of candidate biomarkers for severe adenovirus community-acquired pneumonia by proteomic approach. Heliyon. 2022;8:e10807. doi: 10.1016/j.heliyon.2022.e10807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e10807</ArticleId><ArticleId IdType="pmc">PMC9547224</ArticleId><ArticleId IdType="pubmed">36217477</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery A.H., Li X., Delozier N.L., Toto R.D., Moe O.W., Yee J., Neyra J.A. Sepsis-Associated Acute Kidney Disease and Long-term Kidney Outcomes. Kidney Med. 2021;3:507–514.e1. doi: 10.1016/j.xkme.2021.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xkme.2021.02.007</ArticleId><ArticleId IdType="pmc">PMC8350838</ArticleId><ArticleId IdType="pubmed">34401718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronenberg F. Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function. Curr. Opin. Lipidol. 2017;28:39–45. doi: 10.1097/MOL.0000000000000371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000371</ArticleId><ArticleId IdType="pubmed">27870653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingenhel A., Lhotta K., Neyer U., Heid I.M., Rantner B., Kronenberg M.F., Konig P., von Eckardstein A., Schober M., Dieplinger H., et al. Role of the kidney in the metabolism of apolipoprotein A-IV: Influence of the type of proteinuria. J. Lipid Res. 2006;47:2071–2079. doi: 10.1194/jlr.M600178-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M600178-JLR200</ArticleId><ArticleId IdType="pubmed">16788210</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanova Y., Laikov A., Markelova M., Khadiullina R., Makseev A., Hasanova M., Rizvanov A., Khaiboullina S., Salafutdinov I. Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease. Biomolecules. 2020;10:257. doi: 10.3390/biom10020257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10020257</ArticleId><ArticleId IdType="pmc">PMC7072325</ArticleId><ArticleId IdType="pubmed">32046176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C.W., Chang C.C., Chen H.W., Lin C.Y., Chen J.S. Serum ApoA4 levels predicted the progression of renal impairment in T2DM. Eur. J. Clin. Investig. 2018;48:e12937. doi: 10.1111/eci.12937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.12937</ArticleId><ArticleId IdType="pubmed">29675916</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone R.C. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273:155–156. doi: 10.1001/jama.1995.03520260077036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520260077036</ArticleId><ArticleId IdType="pubmed">7799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959;37:911–917. doi: 10.1139/y59-099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y59-099</ArticleId><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschel G., Grimm J., Muller M., Horing M., Krautbauer S., Weigand K., Liebisch G., Buechler C. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection. Lipids Health Dis. 2022;21:106. doi: 10.1186/s12944-022-01715-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-022-01715-w</ArticleId><ArticleId IdType="pmc">PMC9590217</ArticleId><ArticleId IdType="pubmed">36280840</ArticleId></ArticleIdList></Reference><Reference><Citation>Horing M., Ejsing C.S., Krautbauer S., Ertl V.M., Burkhardt R., Liebisch G. Accurate quantification of lipid species affected by isobaric overlap in Fourier-transform mass spectrometry. J. Lipid Res. 2021;62:100050. doi: 10.1016/j.jlr.2021.100050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jlr.2021.100050</ArticleId><ArticleId IdType="pmc">PMC8010702</ArticleId><ArticleId IdType="pubmed">33600775</ArticleId></ArticleIdList></Reference><Reference><Citation>Horing M., Ejsing C.S., Hermansson M., Liebisch G. Quantification of Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier Transform Mass Spectrometry Utilizing Species-Specific Response Factors. Anal. Chem. 2019;91:3459–3466. doi: 10.1021/acs.analchem.8b05013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.8b05013</ArticleId><ArticleId IdType="pubmed">30707563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmaenner D.A., Arina P., Kleyman A., Page Black L., Salomao R., Tanaka S., Guirgis F.W., Arulkumaran N., Singer M. Association Between Hypocholesterolemia and Mortality in Critically Ill Patients with Sepsis: A Systematic Review and Meta-Analysis. Crit. Care Explor. 2023;5:e0860. doi: 10.1097/CCE.0000000000000860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000860</ArticleId><ArticleId IdType="pmc">PMC9894355</ArticleId><ArticleId IdType="pubmed">36751516</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold K.R., Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Dungan K., Hofland J., et al., editors. Endotext. MDText.com, Inc.; South Dartmouth, MA, USA: 2000.</Citation></Reference><Reference><Citation>Zhang X., Liu H., Hashimoto K., Yuan S., Zhang J. The gut-liver axis in sepsis: Interaction mechanisms and therapeutic potential. Crit. Care. 2022;26:213. doi: 10.1186/s13054-022-04090-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04090-1</ArticleId><ArticleId IdType="pmc">PMC9277879</ArticleId><ArticleId IdType="pubmed">35831877</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Xu M., Liu M., Ji Y., Li Z. TNF-alpha and IL-6 inhibit apolipoprotein A-IV production induced by linoleic acid in human intestinal Caco2 cells. J. Inflamm. 2015;12:22. doi: 10.1186/s12950-015-0069-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-015-0069-0</ArticleId><ArticleId IdType="pmc">PMC4389805</ArticleId><ArticleId IdType="pubmed">25861245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghenu M.I., Dragos D., Manea M.M., Ionescu D., Negreanu L. Pathophysiology of sepsis-induced cholestasis: A review. JGH Open. 2022;6:378–387. doi: 10.1002/jgh3.12771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12771</ArticleId><ArticleId IdType="pmc">PMC9218521</ArticleId><ArticleId IdType="pubmed">35774351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J.K., Zhang Q., Shen X., Zhou J., Wang X., Zhou S.M., Mu X.W. Integrin alphaEbeta7 is involved in the intestinal barrier injury of sepsis. Aging. 2022;14:780–788. doi: 10.18632/aging.203839.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203839</ArticleId><ArticleId IdType="pmc">PMC8833114</ArticleId><ArticleId IdType="pubmed">35042191</ArticleId></ArticleIdList></Reference><Reference><Citation>Orso E., Moehle C., Boettcher A., Szakszon K., Werner T., Langmann T., Liebisch G., Buechler C., Ritter M., Kronenberg F., et al. The satiety factor apolipoprotein A-IV modulates intestinal epithelial permeability through its interaction with alpha-catenin: Implications for inflammatory bowel diseases. Horm. Metab. Res. 2007;39:601–611. doi: 10.1055/s-2007-984466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-984466</ArticleId><ArticleId IdType="pubmed">17712726</ArticleId></ArticleIdList></Reference><Reference><Citation>Peignon G., Thenet S., Schreider C., Fouquet S., Ribeiro A., Dussaulx E., Chambaz J., Cardot P., Pincon-Raymond M., Le Beyec J. E-cadherin-dependent transcriptional control of apolipoprotein A-IV gene expression in intestinal epithelial cells: A role for the hepatic nuclear factor 4. J. Biol. Chem. 2006;281:3560–3568. doi: 10.1074/jbc.M506360200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M506360200</ArticleId><ArticleId IdType="pubmed">16338932</ArticleId></ArticleIdList></Reference><Reference><Citation>Buechler C., Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2020;1865:158658. doi: 10.1016/j.bbalip.2020.158658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2020.158658</ArticleId><ArticleId IdType="pubmed">32058031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P.W., Hung Y.C., Wu T.H., Chen M.H., Yeh C.T., Pan T.L. Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis. Oncotarget. 2017;8:88951–88964. doi: 10.18632/oncotarget.21627.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.21627</ArticleId><ArticleId IdType="pmc">PMC5687660</ArticleId><ArticleId IdType="pubmed">29179490</ArticleId></ArticleIdList></Reference><Reference><Citation>Seishima M., Nishimuraa M., Moriwakib H., Mutob Y., Nomaa A. Reduced intestinal apo A-IV mRNA levels in patients with liver cirrhosis. Int. Hepatol. Commun. 1995;4:153–159. doi: 10.1016/0928-4346(95)00240-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0928-4346(95)00240-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger A.C., Schuller M., Sourij H., Stadler J.T., Hackl G., Eller P., Marsche G. Impact of Sepsis on High-Density Lipoprotein Metabolism. Front. Cell Dev. Biol. 2021;9:795460. doi: 10.3389/fcell.2021.795460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.795460</ArticleId><ArticleId IdType="pmc">PMC8766710</ArticleId><ArticleId IdType="pubmed">35071235</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor R., Zhang C., George D., Kotecha S., Abdelghaffar M., Forster T., Santos Rodrigues P.D., Reisinger A.C., White D., Hamilton F., et al. Low circulatory levels of total cholesterol, HDL-C and LDL-C are associated with death of patients with sepsis and critical illness: Systematic review, meta-analysis, and perspective of observational studies. eBioMedicine. 2024;100:104981. doi: 10.1016/j.ebiom.2024.104981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.104981</ArticleId><ArticleId IdType="pmc">PMC10844818</ArticleId><ArticleId IdType="pubmed">38290288</ArticleId></ArticleIdList></Reference><Reference><Citation>Massy Z.A., de Zeeuw D. LDL cholesterol in CKD—To treat or not to treat? Kidney Int. 2013;84:451–456. doi: 10.1038/ki.2013.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.181</ArticleId><ArticleId IdType="pubmed">23698234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sam R., Zhang L., Tuot D.S., Chaudhry R. The Decrease in Serum Total Cholesterol and Low-Density Lipoprotein (LDL) Concentrations with the Initiation of Hemodialysis Despite a Concomitant Increase in Serum Albumin Concentrations. Cureus. 2023;15:e47272. doi: 10.7759/cureus.47272.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.47272</ArticleId><ArticleId IdType="pmc">PMC10655933</ArticleId><ArticleId IdType="pubmed">38022186</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi A., Franzin R., Fiorentino M., Squiccimarro E., Castellano G., Gesualdo L. Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications. Int. J. Mol. Sci. 2021;22:5980. doi: 10.3390/ijms22115980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115980</ArticleId><ArticleId IdType="pmc">PMC8197836</ArticleId><ArticleId IdType="pubmed">34205975</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangl S., Kollerits B., Lamina C., Meisinger C., Huth C., Stockl A., Dahnhardt D., Boger C.A., Kramer B.K., Peters A., et al. Association between apolipoprotein A-IV concentrations and chronic kidney disease in two large population-based cohorts: Results from the KORA studies. J. Intern. Med. 2015;278:410–423. doi: 10.1111/joim.12380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12380</ArticleId><ArticleId IdType="pubmed">26037138</ArticleId></ArticleIdList></Reference><Reference><Citation>Holven K.B., Roeters van Lennep J. Sex differences in lipids: A life course approach. Atherosclerosis. 2023;384:117270. doi: 10.1016/j.atherosclerosis.2023.117270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2023.117270</ArticleId><ArticleId IdType="pubmed">37730457</ArticleId></ArticleIdList></Reference><Reference><Citation>Laclaustra M., Lopez-Garcia E., Civeira F., Garcia-Esquinas E., Graciani A., Guallar-Castillon P., Banegas J.R., Rodriguez-Artalejo F. LDL Cholesterol Rises with BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data. Diabetes Care. 2018;41:2195–2201. doi: 10.2337/dc18-0372.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-0372</ArticleId><ArticleId IdType="pubmed">30061315</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain A., Ali I., Kaleem W.A., Yasmeen F. Correlation between Body Mass Index and Lipid Profile in patients with Type 2 Diabetes attending a tertiary care hospital in Peshawar. Pak. J. Med. Sci. 2019;35:591–597. doi: 10.12669/pjms.35.3.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.35.3.7</ArticleId><ArticleId IdType="pmc">PMC6572993</ArticleId><ArticleId IdType="pubmed">31258559</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges B., Guerci B., Durlach V., Galland-Jos C., Paul J.L., Lagrost L., Gambert P. Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: A study in normoponderal and obese subjects. J. Lipid Res. 2001;42:2021–2029. doi: 10.1016/S0022-2275(20)31531-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)31531-5</ArticleId><ArticleId IdType="pubmed">11734575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Larson I.A., Ordovas J.M., Barnard J.R., Schaefer E.J. Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations. Atherosclerosis. 2000;151:381–388. doi: 10.1016/S0021-9150(99)00395-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9150(99)00395-0</ArticleId><ArticleId IdType="pubmed">10924714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>